Pharmacokinetic Interaction and Safety Between NVP-1203-R1 and NVP-1203-R2

A Phase I Clinical Trial to Evaluate the Pharmacokinetic Interaction and Safety Between NVP-1203-R1 and NVP-1203-R2 in Healthy Adult Subjects

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04181437

Acronym

Navipharm

Enrollment

Registered

2019-11-29

Start date

2020-05-01

Completion date

2020-05-29

Last updated

2020-09-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Brief summary

The purpose of this study is to compare the pharmacokinetics and safety between NVP-1203-R1 and NVP-1203-R2

Detailed description

pharmacokinetics and safety between NVP-1203-R1 and NVP-1203-R2

Interventions

DRUGNVP-1203-R1

1 tablet, Single oral dosing

DRUGNVP-1203-R2

1 tablet, Single oral dosing

DRUGNVP-1203-R1 and NVP-1203-R2

NVP-1203-R1,1 tablet and NVP-1203-R2, 1 tablet, co-administration, single oral dosing

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

19 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* healthy adult subjects who signed informed consent

Exclusion criteria

* Subjects has a history of allergy reaction of study drug ingredient * Subjects participated in another clinical trial within 6 months prior to administration of the study drug * Inadequate subject for the clinical trial by the investigator's decision

Design outcomes

Primary

Measure	Time frame	Description
Pharmacokinetic interaction	0hours - 24hours	Area under the curve (AUC)

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026